Olanzapine/samidorphan (Qilu Pharmaceutical)

奥氮平/萨米多芬 (齐鲁制药有限公司)

Report date: 2025/01/17 20:00:43

Base Information

Drug NameOlanzapine/samidorphan (Qilu Pharmaceutical)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D1 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists +[4] 
TargetsDopamine D1 receptorDopamine D2 receptorSerotonin 2 (5-HT2) receptor +[4] 
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A